Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$128.27
+0.1%
$112.74
$73.04
$128.52
$8.28B0.891.32 million shs1.35 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$15.89
+1.3%
$14.80
$11.51
$21.50
$2.74B0.52101,418 shs59,320 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$48.77
-0.8%
$48.22
$29.02
$58.38
$3.90B0.5862,349 shs307,079 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$39.19
-0.7%
$36.69
$29.59
$60.37
$3.73B0.26838,182 shs685,292 shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$36.43
+2.6%
$33.71
$16.01
$44.34
$3.94B0.99911,726 shs581,960 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
+0.05%+0.09%+0.53%+57.04%+17.65%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+1.30%+3.61%+8.12%+10.53%-9.28%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-0.77%-1.57%-3.79%+12.79%+57.33%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-0.68%+5.58%+7.66%+20.84%-2.54%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
+2.65%+0.66%+17.03%+14.67%+111.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.7305 of 5 stars
2.14.00.00.02.70.80.6
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1.6186 of 5 stars
2.04.00.00.01.10.01.9
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.3248 of 5 stars
4.31.00.04.41.50.81.3
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
4.158 of 5 stars
3.51.00.03.83.22.50.6
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3.4124 of 5 stars
3.45.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.27
Hold$128.06-0.16% Downside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0019.54% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$65.0033.28% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.93
Moderate Buy$87.00122.00% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.80
Moderate Buy$54.2848.98% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, HCM, BPMC, PTCT, and RARE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$73.00 ➝ $75.00
6/20/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/17/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.28N/AN/A$4.70 per share27.29
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.40$0.29 per share54.62$4.43 per share3.59
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M4.79N/AN/A($14.24) per share-3.42
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$560.23M6.61N/AN/A$2.76 per share14.20
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M10.14N/AN/A$7.68 per share4.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A197.34N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.89N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.517.49N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest ZLAB, HCM, BPMC, PTCT, and RARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
5/6/2025Q1 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.89
3.85
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.40
2.24
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.50%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
4.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million74.90 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,29494.54 million89.34 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869111.08 million105.57 millionOptionable

Recent News About These Companies

Zai Lab FY2025 EPS Estimate Decreased by Cantor Fitzgerald
Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab
FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?
Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$128.27 +0.07 (+0.05%)
Closing price 07/3/2025 02:27 PM Eastern
Extended Trading
$128.27 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$15.89 +0.20 (+1.30%)
Closing price 07/3/2025 01:18 PM Eastern
Extended Trading
$15.94 +0.04 (+0.26%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$48.77 -0.38 (-0.77%)
Closing price 07/3/2025 03:28 PM Eastern
Extended Trading
$48.77 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$39.19 -0.27 (-0.68%)
Closing price 07/3/2025 03:25 PM Eastern
Extended Trading
$39.19 0.00 (0.00%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$36.43 +0.94 (+2.65%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$36.43 0.00 (0.00%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.